<DOC>
	<DOC>NCT02196909</DOC>
	<brief_summary>The objective of the study is to identify the best clinical and biological outcome measures for further therapeutics approaches.</brief_summary>
	<brief_title>Clinical, Biological and NMR Outcome Measures Study for Hereditary Inclusion Body Myopathy Due to Mutation of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine Kinase Gene (GNE)</brief_title>
	<detailed_description />
	<criteria>Must be at least 18 years of age. Must be willing and able to provide consent. Must have a genetic diagnosis of HIBM, GNE myopathy, Quadriceps Sparing Myopathy (QSM), Inclusion Body Myopathy Type 2, distal myopathy with rimmed vacuoles (DMRV), or Nonaka disease. Must be willing and able to comply with all study requirements. Affiliated to or a beneficiary of a social security category Must take part in the HIBMPMP UX001CL401 study Received ManNAc therapy or other similar substance Any unrelated, comorbid disease or condition that, in the view of the investigator, would interfere with study participation or would affect safety. Patients with specific contraindication to MRI (i.e. metallic foreign body, claustrophobiaâ€¦) will be allowed to participate, but MRI will not be performed. Pregnant women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>HIBM</keyword>
	<keyword>GNE</keyword>
</DOC>